Objective: To compare the rates of obesity, impaired fasting glucose (IFG), and type 2
diabetes between second-generation antipsychotic (SGA)-treated and-naive youth …

Background: Antipsychotic drug use in children has doubled from 2001 to 2007 with
concomitant increase in obesity. Second-generation antipsychotic (SGA) medication use is …

Objective: Childhood obesity and its sequelae, including metabolic syndrome, are reaching
epidemic proportions worldwide. Young people treated with antipsychotic medication are …

Objective: To compare the prevalence of metabolic syndrome (MetS) and its components in
second-generation antipsychotic (SGA)-treated and SGA-naive children; and to explore the …

Objectives To estimate metabolic screening rates, predictors of screening, and incidence of
metabolic disturbances in children initiating second-generation antipsychotic (SGA) drug …

Objective: To compare weight and glucose changes of long-term second-generation
antipsychotic (SGA) monotherapy versus polytherapy (switching or combining SGAs) in …

Objective Antipsychotics are associated with weight gain and diabetes. The risk and rate of
diabetes in children and adolescents treated with antipsychotics is unclear. Method A …

Objective: In 2004, the American Diabetes Association (ADA) released treatment guidelines
recommending metabolic screening for children and adolescents before and after initiation …

Objective: Weight gain and metabolic adverse effects of second-generation antipsychotics
(SGAs) have become a major concern, particularly in youth. However, the specific …

Background: Patients receiving second-generation antipsychotics (SGAs) may experience
secondary metabolic effects such as weight gain, as well as changes in lipid and glucose …